Disease control with a second epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) after failure of a first TKI in Asian patients with non-small cell lung cancer (NSCLC)

Andrea La Wong,S.W. Lim,Tan Min Chin,Richie Chuan Teck Soong,Ross A. Soo

Disease control with a second epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) after failure of a first TKI in Asian patients with non-small cell lung cancer (NSCLC)

2016

Andrea La Wong
S.W. Lim
Tan Min Chin
Richie Chuan Teck Soong
Ross A. Soo

18104 Background: Asian NSCLC patients are known to have higher response rates to the EGFR TKI gefitinib (G) and erlotinib (E). Anecdotal reports suggest some activity for a second EGFR TKI after f...

Keywords:

non-small cell lung cancer (NSCLC)
Epidermal growth factor receptor
Pathology
Disease
Tyrosine-kinase inhibitor
Erlotinib
Cancer research
Gefitinib
Medicine
disease control
egfr tyrosine kinase
egfr tki

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations